NewAmsterdam Pharma (NAMS) News Today $17.61 -0.67 (-3.67%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$18.34 +0.73 (+4.12%) As of 05/23/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NAMS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period NewAmsterdam Pharma’s SWOT analysis: obicetrapib stock poised for cardiovascular marketMay 24 at 8:55 PM | investing.com35,657 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Purchased by BNP Paribas Financial MarketsBNP Paribas Financial Markets purchased a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 35,657 shares of the company's stock, valued at approximMay 24 at 3:28 AM | marketbeat.comFrazier Life Sciences Management L.P. Raises Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS)Frazier Life Sciences Management L.P. lifted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 23.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 15,916,418 shares of the company's stock afteMay 23 at 7:51 AM | marketbeat.comBuy Rating for NewAmsterdam Pharma: Obicetrapib’s Potential in Cardiovascular Risk Reduction and Revenue GrowthMay 23 at 4:17 AM | tipranks.com28,517 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Bought by Lazard Asset Management LLCLazard Asset Management LLC acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 28,517 shares of the company's stock, valued at apprMay 23 at 3:58 AM | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Woodline Partners LPWoodline Partners LP lifted its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 108.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,430,782 shares of the company's stock after purchasing an additioMay 22 at 6:17 AM | marketbeat.comHead-To-Head Survey: NewAmsterdam Pharma (NAMS) & The CompetitionMay 22 at 1:47 AM | americanbankingnews.com20,500 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Acquired by OMERS ADMINISTRATION CorpOMERS ADMINISTRATION Corp acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 20,500 shares of the company's stock, valuMay 21, 2025 | marketbeat.comPolar Capital Holdings Plc Raises Stock Position in NewAmsterdam Pharma (NASDAQ:NAMS)Polar Capital Holdings Plc raised its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 16.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,750,000 shares of the company's stocMay 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Decreases Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)Parkman Healthcare Partners LLC trimmed its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 27.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 76,116 shares of the company's stock afteMay 16, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Acquired by Janus Henderson Group PLCJanus Henderson Group PLC increased its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 12.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,736,777 shares of the company's stock after buying an additional 196May 16, 2025 | marketbeat.comMaven Securities LTD Takes $3.86 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)Maven Securities LTD purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 150,000 shares of the company's stock, valued at approximately $3,855,000. Maven Securities LTMay 15, 2025 | marketbeat.comNewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare ConferenceMay 14, 2025 | gurufocus.comNewAmsterdam Pharma to Present at the 2025 RBCCM Global Healthcare ConferenceMay 14, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Acquires Shares of 20,382 NewAmsterdam Pharma (NASDAQ:NAMS)Schonfeld Strategic Advisors LLC bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 20,382 shares of the company's stock, valued at aMay 13, 2025 | marketbeat.comFred Alger Management LLC Acquires Shares of 80,579 NewAmsterdam Pharma (NASDAQ:NAMS)Fred Alger Management LLC bought a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 80,579 shares of the company's stock, valued at appMay 12, 2025 | marketbeat.com35,068 Shares in NewAmsterdam Pharma (NASDAQ:NAMS) Bought by Crestline Management LPCrestline Management LP acquired a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 35,068 shares of the company's stock, valueMay 12, 2025 | marketbeat.comFcpm Iii Services B.V. Has $272.35 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)Fcpm Iii Services B.V. trimmed its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 10.4% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 10,597,181 shares of the company's stock after selling 1,234,2May 11, 2025 | marketbeat.comScotiabank Sticks to Their Buy Rating for NewAmsterdam Pharma Company (NAMS)May 11, 2025 | theglobeandmail.comDeerfield Management Company L.P. Series C Grows Position in NewAmsterdam Pharma (NASDAQ:NAMS)Deerfield Management Company L.P. Series C boosted its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 378.4% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,314,340 shares of the company's stockMay 10, 2025 | marketbeat.comNewAmsterdam Pharma (NAMS) to Release Quarterly Earnings on WednesdayNewAmsterdam Pharma (NASDAQ:NAMS) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-newamsterdam-pharma-stock/)May 9, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Sold by Alyeska Investment Group L.P.Alyeska Investment Group L.P. decreased its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 62.8% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 114,707 shares of the company's stock after selling 193,451May 9, 2025 | marketbeat.comAxa S.A. Sells 66,387 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Axa S.A. trimmed its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 19.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 278,266 shares of the company's stock after selling 66,387 shares during the quarter.May 9, 2025 | marketbeat.comDecoding NewAmsterdam Pharma Co NV (NAMS): A Strategic SWOT InsightMay 9, 2025 | gurufocus.comBuy Rating Affirmed for NewAmsterdam Pharma: Strategic Progress and Financial Stability Drive ConfidenceMay 8, 2025 | tipranks.comNewAmsterdam Pharma’s Promising Phase III Results and Strategic Plans Garner Buy RatingMay 8, 2025 | tipranks.comNewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial ResultsMay 8, 2025 | globenewswire.comCutter Capital Management LP Buys Shares of 337,152 NewAmsterdam Pharma (NASDAQ:NAMS)Cutter Capital Management LP purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 337,152 sharesMay 8, 2025 | marketbeat.comTudor Investment Corp ET AL Buys New Shares in NewAmsterdam Pharma (NASDAQ:NAMS)Tudor Investment Corp ET AL purchased a new position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 52,208 shares of the company's sMay 8, 2025 | marketbeat.comNewAmsterdam Pharma Presents Promising Phase 3 Trial DataMay 7, 2025 | tipranks.comNewAmsterdam Pharma Announces Late-Breaking Data from BROADWAY and TANDEM Pivotal Studies Published in Leading Medical Journals and Presented at the European Atherosclerosis Society (EAS) Congress 2025May 7, 2025 | globenewswire.comBellevue Group AG Purchases 17,300 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Bellevue Group AG boosted its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 224.7% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 25,000 shares of the company's stock after puMay 7, 2025 | marketbeat.comAcuta Capital Partners LLC Makes New $1.29 Million Investment in NewAmsterdam Pharma (NASDAQ:NAMS)Acuta Capital Partners LLC acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 50,000 shares of the company's stock, valued at approximately $1,285,000. NewAmMay 4, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) is RA Capital Management L.P.'s 7th Largest PositionRA Capital Management L.P. boosted its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 9.7% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 8,845,000 shares of the company's stock after acquirinMay 3, 2025 | marketbeat.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2025 | globenewswire.comMonashee Investment Management LLC Invests $1.29 Million in NewAmsterdam Pharma (NASDAQ:NAMS)Monashee Investment Management LLC purchased a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 50,000 shares of the company's stock, valueMay 2, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives Average Rating of "Buy" from AnalystsShares of NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) have been given a consensus recommendation of "Buy" by the six research firms that are covering the company, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12 month price objectMay 2, 2025 | marketbeat.comNewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS CongressApril 30, 2025 | gurufocus.comNewAmsterdam Pharma to Present New Clinical and Preclinical Data at 93rd EAS CongressApril 30, 2025 | globenewswire.comNewAmsterdam Pharma Company N.V. (NAMS): Among Billionaire Andreas Halvorsen’s Stock Picks With Huge Upside PotentialApril 29, 2025 | insidermonkey.comInvesco Ltd. Invests $3.87 Million in NewAmsterdam Pharma (NASDAQ:NAMS)Invesco Ltd. acquired a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 150,559 shares of the company's stock, valued at approximApril 29, 2025 | marketbeat.comDecheng Capital LLC Has $19.79 Million Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)Decheng Capital LLC raised its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 30.5% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 770,000 shares of the company's stock after purchasing an addiApril 28, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Sells 330,000 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Adage Capital Partners GP L.L.C. lessened its position in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 23.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,050,000 shares of the company's stock afteApril 28, 2025 | marketbeat.comWalleye Capital LLC Has $270,000 Position in NewAmsterdam Pharma (NASDAQ:NAMS)Walleye Capital LLC decreased its holdings in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 77.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 10,506 shares of the company's stock after selling 36,441 shApril 28, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by JPMorgan Chase & Co.JPMorgan Chase & Co. grew its position in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 172.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 60,977 shares of the company's stock after purchasing an additiApril 28, 2025 | marketbeat.comGMT Capital Corp Has $7.33 Million Position in NewAmsterdam Pharma (NASDAQ:NAMS)GMT Capital Corp cut its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 65.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 285,136 shares of the company's stock after selling 543,900 shares during the period. NewAmsterdam PharmApril 25, 2025 | marketbeat.comNewAmsterdam Pharma (NASDAQ:NAMS) Shares Purchased by Marshall Wace LLPMarshall Wace LLP raised its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 161.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 288,446 shares of the company's stock after purchasing an additionalApril 25, 2025 | marketbeat.comJump Financial LLC Makes New Investment in NewAmsterdam Pharma (NASDAQ:NAMS)Jump Financial LLC purchased a new stake in shares of NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 25,401 shares of the company's stock, valued atApril 25, 2025 | marketbeat.comSlate Path Capital LP Purchases New Holdings in NewAmsterdam Pharma (NASDAQ:NAMS)Slate Path Capital LP acquired a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 319,000 shares of the company's stock, valued at approximately $8,198,000. Slate Path Capital LP owned approximatApril 24, 2025 | marketbeat.comEversept Partners LP Sells 31,995 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)Eversept Partners LP lessened its stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 10.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 275,362 shares of the company's stock after selling 31,995 shares duringApril 24, 2025 | marketbeat.com Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address NAMS Media Mentions By Week NAMS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NAMS News Sentiment▼1.280.75▲Average Medical News Sentiment NAMS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NAMS Articles This Week▼85▲NAMS Articles Average Week Get NewAmsterdam Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for NAMS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Roivant Sciences News Revolution Medicines News Elanco Animal Health News Blueprint Medicines News BridgeBio Pharma News Verona Pharma News Telix Pharmaceuticals Limited American Depositary Shares News TG Therapeutics News Grifols News Lantheus News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NAMS) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy NAMS Stock Free NAMS Stock Alerts